^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PORT-6

i
Other names: PORT-6, TT-10
Associations
Trials
Company:
Portage
Drug class:
Adenosine A2A receptor antagonist
Associations
Trials
7ms
ADPORT-601: TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
P1/2, N=90, Active, not recruiting, Portage Biotech | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
PORT-6
over1year
TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
P1/2, N=90, Recruiting, Portage Biotech | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
PORT-6
over2years
TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
P1/2, N=90, Not yet recruiting, Tarus Therapeutics, Inc. | Initiation date: Sep 2021 --> Aug 2022
Trial initiation date
|
CD4 (CD4 Molecule)
|
PORT-6
over2years
Adenosine receptor antagonists A2AR (TT-10) and A2BR (TT-4) demonstrate anti-tumor activity in 4T1-induced syngeneic breast cancer mouse model (AACR 2022)
TT-10 & TT-4 alone was superior (p<0.05) to the VC as well as single agent anti-PD-1 in slowing tumor growth, which was further supported by the increase in T-cell activity observed in the end of study TIL analysis. Lastly, striking reductions in MDSC populations were also observed in both TT-10 & TT-4 treated mice, when compared to single agent anti-PD-1 and the VC.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ITGAM (Integrin, alpha M) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
PORT-6 • PORT-7
over3years
Clinical • New P1/2 trial
|
CD4 (CD4 Molecule)
|
PORT-6